Lan Thi Hanh Phi,* Yoseph Toni Wijaya,* Ita Novita Sari, Kwang Seock Kim, Ying-Gui Yang, Min-Woo Lee, Hyog Young Kwon

Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan, Republic of Korea

*These authors contributed equally to this work

Correspondence: Hyog Young Kwon; Min-Woo LeeSoonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, 25 Bongjeong-ro, Cheonan, Chungcheongnam-do 31151, Republic of KoreaTel +82-41-413-5021; +82-41-413-5029Email hykwon@sch.ac.kr; mwlee12@sch.ac.kr

Background: Cancer stem cells (CSCs) have been proposed as central drivers of cancer relapse in many cancers. In the present study, we investigated the inhibitory effect of 20(R)-Ginsenoside Rg3 (Rg3R), a major active component of ginseng saponin, on CSC-like cells and the Epithelial-Mesenchymal Transition (EMT) in colorectal cancer (CRC).Methods: The effects of ginsenoside Rg3R on the colony-forming, migration, invasion, and wound-healing abilities of CRC cells were determined in HT29 and SW620 cell lines in vitro. Further, ginsenoside Rg3R was given intraperitoneally at 5mg/kg of mouse body weight to check its effect on the metastasis of CRC cells in vivo.Results: Ginsenoside Rg3R significantly inhibited CSC properties, but did not affect cell proliferation. Moreover, ginsenoside Rg3R treatment significantly inhibited the motility of CRC cells based on migration, invasion, and wound-healing assays. The inhibitory effects of ginsenoside Rg3R on CRC are potentially mediated by significant down-regulation of the expression of stemness genes and EMT markers in CRC cells in a SNAIL-dependent manner. Furthermore, ginsenoside Rg3R treatment decreased both the number and size of tumor nodules in the liver, lung, and kidney tissues in a metastasis mouse model.Conclusion: These findings highlighted the potential use of ginsenoside Rg3R in clinical applications for colorectal cancer treatment.

Keywords: colorectal cancer, ginsenoside Rg3R, CSCs, EMT

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
20(R)-Ginsenoside Rg3 Influences Cancer Stem Cell Properties and the E | OTT - Dove Medical Press